<?xml version="1.0" encoding="UTF-8"?>
<ref id="B153-biomedicines-08-00109">
 <label>153.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Faber</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Lamirande</surname>
    <given-names>E.W.</given-names>
   </name>
   <name>
    <surname>Roberts</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Rice</surname>
    <given-names>A.B.</given-names>
   </name>
   <name>
    <surname>Koprowski</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Dietschold</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Schnell</surname>
    <given-names>M.J.</given-names>
   </name>
  </person-group>
  <article-title>A single imunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</article-title>
  <source>J. Gen. Virol.</source>
  <year>2005</year>
  <volume>86</volume>
  <fpage>1435</fpage>
  <lpage>1440</lpage>
  <pub-id pub-id-type="doi">10.1099/vir.0.80844-0</pub-id>
  <pub-id pub-id-type="pmid">15831955</pub-id>
 </element-citation>
</ref>
